Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Sandoz introduces Act4Biosimilars Action Plan to accelerate patient access to biosimilar medicines

Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22

Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr

Specialty Chemicals grew 38% YoY for FY23

SERDA therapeutics submits IND for wound debridement agent

Clinical studies are expected to start in Q2 2023.

SMS Pharma revenue down 9%

Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market

Strong order book in CMO segments for J.B. Chemicals & Pharmaceuticals, says Prabhudas Lilladher

The company sees the business reaching $100mn

Themis Medicare revenue down 15.26%; Profit down 7.76%

For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%

Astec LifeSciences plan Capex of Rs. 300 - 350 Cr

R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side